CAPTRUST Financial Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.59M | Buy |
19,577
+2,202
| +13% | +$406K | 0.01% | 915 |
|
|
2025
Q4 | $3.06M | Buy |
17,375
+843
| +5% | +$138K | 0.01% | 884 |
|
|
2025
Q3 | $2.32M | Buy |
16,532
+1,937
| +13% | +$262K | ﹤0.01% | 953 |
|
|
2025
Q2 | $1.83M | Buy |
14,595
+2,013
| +16% | +$251K | ﹤0.01% | 1010 |
|
|
2025
Q1 | $1.72M | Buy |
12,582
+2,870
| +30% | +$410K | ﹤0.01% | 974 |
|
|
2024
Q4 | $1.49M | Buy |
9,712
+3,218
| +50% | +$543K | ﹤0.01% | 1026 |
|
|
2024
Q3 | $1.26M | Sell |
6,494
-815
| -11% | -$171K | ﹤0.01% | 1061 |
|
|
2024
Q2 | $1.69M | Sell |
7,309
-165
| -2% | -$35.9K | 0.01% | 892 |
|
|
2024
Q1 | $1.61M | Sell |
7,474
-2,686
| -26% | -$629K | 0.01% | 895 |
|
|
2023
Q4 | $2.63M | Sell |
10,160
-174
| -2% | -$42.7K | 0.01% | 798 |
|
|
2023
Q3 | $2.66M | Sell |
10,334
-757
| -7% | -$202K | 0.01% | 747 |
|
|
2023
Q2 | $3.16M | Buy |
11,091
+2,538
| +30% | +$756K | 0.01% | 657 |
|
|
2023
Q1 | $2.38M | Sell |
8,553
-233
| -3% | -$64.5K | 0.01% | 682 |
|
|
2022
Q4 | $2.43M | Buy |
8,786
+1,028
| +13% | +$290K | 0.01% | 646 |
|
|
2022
Q3 | $2.07M | Buy |
7,758
+650
| +9% | +$138K | 0.01% | 658 |
|
|
2022
Q2 | $1.45M | Buy |
7,108
+1,281
| +22% | +$262K | 0.01% | 696 |
|
|
2022
Q1 | $1.23M | Sell |
5,827
-866
| -13% | -$188K | 0.01% | 765 |
|
|
2021
Q4 | $1.61M | Buy |
6,693
+94
| +1% | +$24.2K | 0.01% | 629 |
|
|
2021
Q3 | $1.87M | Buy |
6,599
+557
| +9% | +$183K | 0.02% | 537 |
|
|
2021
Q2 | $2.09M | Sell |
6,042
-130
| -2% | -$39.4K | 0.02% | 493 |
|
|
2021
Q1 | $1.73M | Buy |
6,172
+1,009
| +20% | +$272K | 0.02% | 508 |
|
|
2020
Q4 | $1.26M | Buy |
5,163
+334
| +7% | +$86.2K | 0.02% | 531 |
|
|
2020
Q3 | $1.38M | Sell |
4,829
-320
| -6% | -$89.3K | 0.02% | 420 |
|
|
2020
Q2 | $1.36M | Buy |
5,149
+1,046
| +25% | +$314K | 0.02% | 426 |
|
|
2020
Q1 | $1.2M | Sell |
4,103
-168
| -4% | -$51K | 0.03% | 386 |
|
|
2019
Q4 | $1.26M | Buy |
4,271
+2,971
| +229% | +$824K | 0.02% | 463 |
|
|
2019
Q3 | $303K | Buy |
1,300
+21
| +2% | +$4.89K | 0.01% | 490 |
|
|
2019
Q2 | $299K | Sell |
1,279
-106
| -8% | -$24.5K | 0.01% | 481 |
|
|
2019
Q1 | $327K | Sell |
1,385
-414
| -23% | -$130K | 0.01% | 429 |
|
|
2018
Q4 | $541K | Buy |
1,799
+154
| +9% | +$49.1K | 0.03% | 298 |
|
|
2018
Q3 | $581K | Buy |
1,645
+1,291
| +365% | +$444K | 0.03% | 288 |
|
|
2018
Q2 | $103K | Sell |
354
-230
| -39% | -$64.7K | 0.01% | 503 |
|
|
2018
Q1 | $156K | Buy |
584
+229
| +65% | +$71.1K | 0.01% | 356 |
|
|
2017
Q4 | $113K | Buy |
355
+335
| +1,675% | +$107K | 0.01% | 424 |
|
|
2017
Q3 | $6K | Buy |
+20
| New | +$5.92K | ﹤0.01% | 466 |
|
Other funds holding BIIB
VCM
VPM
CAPTRUST Financial Advisors's BIIB Position: Q1 2026 in Review
CAPTRUST Financial Advisors increased its Biogen (BIIB) stake by 13% in Q1 2026, buying an estimated $406K and bringing the position to 19,577 shares worth $3.59M. The position accounts for 0.01% of the portfolio, ranked #915.
CAPTRUST Financial Advisors first reported a position in BIIB in Q3 2017 and has held it in 35 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- CAPTRUST Financial Advisors held 19,577 shares of Biogen worth $3.59M as of Q1 2026.
- CAPTRUST Financial Advisors bought 2,202 Biogen shares in Q1 2026, an estimated $406K.
- Biogen made up 0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #915 holding.
- CAPTRUST Financial Advisors first reported a position in Biogen in Q3 2017 and has held it in 35 quarters since.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.